"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at CAV chemotherapy versus paclitaxel and carboplatin for small cell lung cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was comparing the combination of 3 drugs called vincristine, doxorubicin and cyclophosphamide (CAV) with a combination of 2 drugs called paclitaxel and carboplatin (PC), to see which worked best for small cell lung cancer.
Small cell lung cancer responds very well to chemotherapy. But many patients will not be cured and the treatment aims to control the disease and its symptoms for as long as possible. So the treatment should not cause too many side effects.
The aims of this trial were to see which of the 2 drug combinations
- Was better at controlling the disease for longer
- Had fewer side effects
Summary of results
The trial team found that more people who had paclitaxel and carboplatin (PC) were alive after one year.
The trial recruited 219 patients. Half had PC chemotherapy, the other half had CAV. The cancer got smaller in about 6 out of 10 people (60%) in both groups. But on average, people who had PC lived longer.
People having PC had more nerve damage (
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Nick Thatcher
Manchester Lung Tumour Group